SCHEMBL3370683

SCHEMBL3370683

Cc1c(-c2ccccc2)nc(N)c(C#N)c1-c1ccc(Cl)cc1Cl

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.59
ALDH1A1 P00352 6/20 0.58
HSD17B10 Q99714 4/20 0.58
MEN1 O00255 3/20 0.58
KMT2A Q03164 3/20 0.58
HPGD P15428 3/20 0.58
CASP1 P29466 1/20 0.58
BLM P54132 1/20 0.58
GSK3A P49840 1/20 0.57
GSK3B P49841 1/20 0.57
DYRK1A Q13627 1/20 0.57
CLK4 Q9HAZ1 1/20 0.57
ADORA2A P29274 8/20 0.52
ADRA2A P08913 1/20 0.52
HTT P42858 1/20 0.52
ADORA1 P30542 8/20 0.52
ADORA2B P29275 2/20 0.52
MAPT P10636 2/20 0.47
PPARG P37231 1/20 0.47
STAT3 P40763 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3372013 0.84 KDM4E (0.69) KDM4EALDH1A1HSD17B10MEN1KMT2A
SCHEMBL3369894 0.81 DPP4 (0.63) CYP1A2CYP2C9CYP2C19
SCHEMBL3372730 0.78 DPP4 (0.65) HSD17B10GSK3AGSK3BDYRK1ACLK4
SCHEMBL6224104 0.78 DPP4 (0.65) KDM4EALDH1A1MEN1KMT2AHPGD
SCHEMBL3369385 0.78 ADORA1 (0.78) KDM4EMEN1KMT2AHPGDGSK3A
SCHEMBL5483521 0.76 KDM4E (0.64) KDM4EALDH1A1HSD17B10MEN1KMT2A
SCHEMBL27903042 0.75 KDM4E (0.67) KDM4EALDH1A1HSD17B10MEN1KMT2A
SCHEMBL6223803 0.74 GSK3A (0.52) KDM4EALDH1A1MEN1KMT2AHPGD
SCHEMBL6222249 0.74 HPGD (0.65) KDM4EALDH1A1MEN1KMT2AHPGD
SCHEMBL3368098 0.74 DPP4 (0.68) KDM4EALDH1A1HSD17B10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1476435-B1 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-06-30 EP disclosed
US-7022718-B2 Pyridine and pyrimidine derivatives HOFFMANN-LA ROCHE INC. (US) 2006-04-04 US disclosed
US-20050143405-A1 Pyridine and pyrimidine derivatives BOEHRINGER MARKUS (CH) 2005-06-30 US disclosed
US-6867205-B2 Pyridine and pyrimidine derivatives HOFFMAN-LA ROCHE INC. (US) 2005-03-15 US disclosed
EP-1476435-A1 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-11-17 EP disclosed
WO-2003068757-A9 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES HOFFMANN LA ROCHE (CH) 2004-10-07 WO disclosed
US-20030216382-A1 Pyridine and pyrimidine derivatives HOFFMAN-LA ROCHE INC. 2003-11-20 US disclosed
WO-2003068757-A1 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216382-A1 Pyridine and pyrimidine derivatives DPP4, GPR119, G6PC1 KDM4E 1329/4885ALDH1A1 152/4885HSD17B10 1818/4885
US-20050143405-A1 Pyridine and pyrimidine derivatives DPP4, GPR119, PDXK KDM4E 916/4885ALDH1A1 330/4885HSD17B10 2183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.